REVIEW PAPER
New trends in pharmacotherapy of lumbar spine pain syndromes
Online publication date: 2010-11-16
Reumatologia 2010;48(5):345-348
KEYWORDS
ABSTRACT
Current opinions about radicular pathology and origin of pain in degenerative disc disease are presented. Increasingly, many authors point to the inflammatory process in pathophysiology of morphological and functional nerve root changes and radicular pain origin. Now it is clear that the nucleus pulposus has antigenic properties and may be a source of many inflammatory mediators, particularly TNFα. Observations from the first clinical investigations including biological therapy of radicular pain and root dysfunction in disc disease are favourable, but too limited. Therefore many more clinical multicentre, randomized trials are needed, to answer in depth the question about the effectiveness and usefulness of biological drugs in routine clinical therapy of radicular pain syndrome
REFERENCES (23)
1.
Mulleman D, Mammou S, Griffoul I, et al. Pathophysiology of disk-related sciatica. I. evidence supporting a chemical component. Joint Bone Spine 2006; 73: 151-158. .
2.
Goupille P, Mulleman D, Valat JP. Radiculopathy associated with disc herniation. Ann Rheum Dis 2006; 65: 141-143. .
3.
Goupille P, Mulleman D, Paintaud G, et al. Can sciatica induced by disc herniation be treated with tumor necrosis factor α blockade? Arthritis Rheum 2007; 12: 3887-3895. .
4.
Benoist M. The natural history of lumbar disc herniation and radiculopathy. Joint Bone Spine 2002; 69: 155-160. .
5.
Pyskło B, Styczyński T. Wpływ współistniejącego zespołu rzekomokorzeniowego w przypadkach przepuklin lędźwiowych krążków międzykręgowych (plkm) na wyniki terapii trakcyjnej. Neur Neurochir Pol 1998; 32: 1449-1460. .
6.
Murata Y, Onda A, Rydevik B, et al. Selective inhibition of tumor necrosis factor-α prevents nucleus pulposus-induced histologic changes in the dorsal root ganglion. Spine 2004; 22: 2477-2484. .
7.
Styczyński T, Gasik R, Pyskło B. Niektóre aspekty farmakoterapii bólów w okolicy lędźwiowo-krzyżowej związanych z chorobą zwyrodnieniową kręgosłupa. Reumatologia 2006; 44: 335-338. .
8.
Olmarker K, Blomquist J, Strõmberg J, et al. Inflammatogenic properties of nucleus pulposus. Spine 1995; 20: 665-669. .
9.
Olmarker K, Rydevik B. Selective inhibition of tumor necrosis factor-α prevents nucleus pulposus-induced thrombus formation, intraneural edema, and reduction of nerve conduction velocity. Spine 2001; 26: 863-869. .
10.
Weiler CH, Nerlich AG, Bachmeier BE, et al. Expression and distribution of tumor necrosis factor alpha in human lumbar intervertebral discs: a study in surgical specimen and autopsy controls. Spine 2004; 29: 44-54. .
11.
Baogan P, Jianhu H, Shuxun H, et al. Possible pathogenesis of painful intervertebral disc degeneration. Spine 2006; 31: 560-566. .
12.
Hoyland JA, Le Maitre C, Freemont AJ. Investigation of the role of IL-1 and TNF in matrix degradation in the intervertebral disc. Rheumatology 2008; 47: 809-814. .
13.
Yoshida M, Nakamura T, Sei A, et al. Intervertebral disc cells produce tumor necrosis factor alpha, interleukin-1, and monocyte chemoattractant protein-1 immediately after herniation: an experimental study using a new hernia model. Spine 2005; 30: 55-61. .
14.
Cush J, Kavanaugh A. TNF-α blocking therapies. In: Rheumatology, ed. Hochberg MC, Silman AJ, et al. Mosby Elsevier 2008: 501-517. .
15.
Mulleman D, Mammou S, Griffoul I, et al. Pathophysiology of disk-related low back pain and sciatica. II. Evidence supporting treatment with TNF-α antagonists. Joint Bone Spine 2006; 73: 270-277. .
16.
Olmarker K, Larsson K. Tumor necrosis factor α and nucleus-pulposus – induced nerve root injury. Spine 1998; 23: 2538-2544. .
17.
Dziewit T, Kucharz EJ. Rola antagonistów interleukiny 1 w leczeniu chorób zapalnych – dotychczasowe doświadczenia i perspektywy. Reumatologia 2009; 47: 151-157. .
18.
Atcheson SG, Dymeck T. Rapid resolution of chronic sciatica with intravenous infliximab after failed epidural steroid injections. Spine 2004; 29: 248-250. .
19.
Karppinen J, Korhonen T, Malmivaara A, et al. Tumor necrosis factor-alpha monoclonal antibody, infliximab, used to manage severe sciatica, Spine 2003; 28: 750-754. .
20.
Korhonen T, Karppinen J, Paimela L, et al. The treatment of disc herniation-induced sciatica with infliximab: one-year follow-up results of FIRST II, a randomized controlled trial. Spine 2006; 31: 2759-2766. .
21.
Korhonen T, Karppinen J, Paimela L, et al. The treatment of disc herniation-induced sciatica with infliximab. Results of a randomized, controlled, 3-month follow-up study. Spine 2005; 24: 2724-2728. .
22.
Genevay S, Stingelin S, Gabay C. Efficacy of etanercept in the treatment of acute, severe sciatica: a pilot study. Ann Rheum Dis 2004; 63: 1120-1123. .
23.
Genevay S, Viatte S, Finckh A, et al. Adalimumab in severe and acute sciatica: a multicentre, randomised, double-blind, placebo-controlled trial. Arthritis Rheum 2010; 62: 2339-2346.
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Share
RELATED ARTICLE
| eISSN: | 2084-9834 |
| ISSN: | 0034-6233 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
